Publication | Open Access
Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
32
Citations
14
References
2022
Year
Emicizumab could reduce bleeds in pediatric patients with/without FVIII inhibitors and eliminate target joints.
| Year | Citations | |
|---|---|---|
Page 1
Page 1